Deqi Pharmaceuticals will publish the research results of ATG-101 and ATG-017 at the 2021 SITC annual meeting

Shanghai and Hong Kong October 15, 2021/PRNewswire/ - From November 10 to 14, 2021, the 36th Society for Cancer Immunotherapy (SITC 2021) will be held in Washington, USA

The poster details are as follows:

Abstract Number: 227

Title: Computational semi-mechanical pharmacology model of PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of solid tumors and non-Hodgkin's lymphoma (NHL)

Publication time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)

Speaker: Dr.

First author: Dr.

Abstract Number: 608

Title: Synergistic effect of ATG-017 (ERK1/2 inhibitor) and immune checkpoint inhibitor in preclinical cancer models

Publication time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)

Speaker: Dr.

First author: Dr.

Abstract Number: 893

Title: As a new PD-L1/4-1BB bispecific antibody, ATG-101 enhances anti-tumor immunity through immune checkpoint suppression and PDL1-directed 4-1BB activation

Publication time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)

Speaker: Dr.

First author: Dr.

About ATG-101

ATG-101 is a new PD-L1/4-1BB bispecific antibody, which is being developed for the treatment of various types of solid and hematological tumors

About ATG-017

ATG-017 (AZD0364) is a potent and selective small molecule inhibitor that acts on extracellular signal-regulated kinase 1 and 2 (ERK1/2)

About Deqi Pharmaceutical

Deqi Pharmaceutical Co.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article

Source: Deqi Pharmaceutical Co.